PCN340 TREATMENT OUTCOMES IN LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK PATIENTS WHO SUBSEQUENTLY PROGRESSED: REAL-WORLD EVIDENCE FROM EUROPE AND THE US

Abstract

To describe outcomes of treatment for locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) in patients who completed frontline, locoregional treatment. A real-world cross-sectional survey was conducted in France, Germany, the UK, Spain, Italy (EU5) and the US from April–September 2016. Inclusion criteria considered oncologists, qualified for 5-35 years, who made treatment decisions for ≥10 SCCHN patients/month. Physicians provided information on their next 8 consecutive SCCHN patients receiving 1L R/M treatment after previously receiving treatment for locally advanced disease. All analyses are descriptive. Physicians (n=213) provided data on 557 patients (n=458 EU5, n=99 US). Mean patient age was 63.1 years; 68% of patients were male. 68% (n=377) of patients did not receive surgery (un-resected), of whom 78% had Eastern Cooperative Oncology Group scores (ECOG) of 0-1 at diagnosis. At initiation of subsequent R/M treatment, 66% of patients who were un-resected in LA setting had ECOG 0-1. 53% of un-resected patients received chemoradiation (CRT) in the LA setting: 29% achieved complete response; 36% had partial response/stable disease; and 32% had progressive disease. In un-resected patients who did not receive CRT (non-CRT) in the LA SCCHN setting, the respective percentages were 17%, 35% and 35% of patients. Mean duration of therapy was 14.1 weeks in patients who received CRT and 14.6 weeks in non-CRT patients. Median time to next treatment was 23.7 weeks in patients who received CRT in the LA setting, and 5.9 weeks in non-CRT patients. CRT is used as frontline treatment for the majority of un-resected LA SCCHN patients who subsequently progressed. While physicians reported improved treatment outcomes and longer time to initiation next treatment in CRT vs. non-CRT patients, achievement of complete response remains low (<50%). Therefore, there remains a need for more efficacious treatment modalities in the frontline LA SCCHN setting.